Recent advances in applications of liquid chromatography-tandem mass spectrometry to the analysis of reactive drug metabolites

Chemico-Biological Interactions

Volumn 179, Issue 1, 2009, Pages 25-37

  Ma, Shuguang ^a   Zhu, Mingshe ^b  

^a AMGEN INC   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Accurate mass; Constant neutral loss scan; Glutathione conjugates; LC MS MS; LTQ; LTQ Orbitrap; Mass defect filter; Multiple reaction monitoring; Precursor ion scan; Q TOF; Q trap; Reactive metabolites

Indexed keywords

CLOZAPINE; DICLOFENAC; DRUG METABOLITE; GLUTATHIONE; IMIPRAMINE; STABLE ISOTOPE;

ARTICLE; CHEMICAL MODIFICATION; CHEMICAL REACTION; DRUG STRUCTURE; DRUG TRANSFORMATION; HIGH THROUGHPUT SCREENING; HUMAN; ION TRAP MASS SPECTROMETRY; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; LIVER MICROSOME METABOLISM; METABOLIC ACTIVATION; QUADRUPOLE MASS SPECTROMETRY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY;

BIOTRANSFORMATION; CHROMATOGRAPHY, LIQUID; PHARMACOKINETICS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 59649106977     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2008.09.014     Document Type: Article

References (95)

1. Guengerich F.P. Generation of reactive intermediates. J. Biochem. Mol. Toxicol. 19 (2005) 173-174
2. Kalgutkar A.S., Gardner I., Obach R.S., Shaffer C.L., Callegari E., Henne K.R., Mutlib A.E., Dalvie D.K., Lee J.S., Nakai Y., O'Donnell J.P., Boer J., and Harriman S.P. A comprehensive listing of bioactivation pathways of organic functional groups. Curr. Drug Metab. 6 (2005) 161-225
3. Nelson S.D. Structure toxicity relationships-how useful are they in predicting toxicities of new drugs. In: Dansette P.M., Snyder R., Delaforge M., Goibson G.G., Greom H., Jollow D.J., Monks T.J., and Sipes I.G. (Eds). Biological Reactive Intermediates VI: Chemical and Biological Mechanisms in Susceptibility to and Prevention of Environmental Diseases (2001), Kluwer Academic/Plenum Publishers, New York 33-44
4. Zhou S., Chan E., Duan W., Huang M., and Chen Y.Z. Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metab. Rev. 37 (2005) 41-213
5. Erve J.C. Chemical toxicology: reactive intermediates and their role in pharmacology and toxicology. Expert Opin. Drug Metab. Toxicol. 2 (2006) 923-946
6. Ju C., and Uetrecht J.P. Mechanism of idiosyncratic drug reactions: reactive metabolite formation, protein binding and the regulation of the immune system. Curr. Drug Metab. 3 (2002) 367-377
7. Williams D.P., Kitteringham N.R., Naisbitt D.J., Pirmohamed M., Smith D.A., and Park B.K. Are chemically reactive metabolites responsible for adverse reactions to drugs?. Curr. Drug Metab. 3 (2002) 351-366
8. Uetrecht J. Idiosyncratic drug reactions: past, present, and future. Chem. Res. Toxicol. 21 (2008) 84-92
9. Walgren J.L., Mitchell M.D., and Thompson D.C. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit. Rev. Toxicol. 35 (2005) 325-361
10. Evans D.C., Watt A.P., Nicoll-Griffith D.A., and Baillie T.A. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 17 (2004) 3-16
11. Park K.B., Dalton-Brown E., Hirst C., and Williams D.P. Selection of new chemical entities with decreased potential for adverse drug reactions. Eur. J. Pharmacol. 549 (2006) 1-8
12. Baillie T.A. Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism. Chem. Res. Toxicol. 21 (2008) 129-137
13. Uetrecht J. Screening for the potential of a drug candidate to cause idiosyncratic drug reactions. Drug Discov. Today 8 (2003) 832-837
14. Guengerich F.P., and MacDonald J.S. Applying mechanisms of chemical toxicity to predict drug safety. Chem. Res. Toxicol. 20 (2007) 344-369
15. Baillie T.A. Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology. Chem. Res. Toxicol. 19 (2006) 889-893
16. Evans D.C., and Baillie T.A. Minimizing the potential for metabolic activation as an integral part of drug design. Curr. Opin. Drug Discov. Devel. 8 (2005) 44-50
17. Ma S., and Subramanian R. Detecting and characterizing reactive metabolites by liquid chromatography/tandem mass spectrometry. J. Mass Spectrom. 41 (2006) 1121-1139
18. Takakusa H., Masumoto H., Yukinaga H., Makino C., Nakayama S., Okazaki O., and Sudo K. Covalent binding and tissue distribution/retention assessment of drugs associated with idiosyncratic drug toxicity. Drug Metab. Dispos. 36 (2008) 1770-1779
19. Staack R.F., and Hopfgartner G. New analytical strategies in studying drug metabolism. Anal. Bioanal. Chem. 388 (2007) 1365-1380
20. Nassar A.E., Kamel A.M., and Clarimont C. Improving the decision-making process in structural modification of drug candidates: reducing toxicity. Drug Discov. Today 9 (2004) 1055-1064
21. Zhang Z., and Gan J. Protocols for assessment of in vitro and in vivo bioactivation potential of drug candidates. In: Zhang D., Zhu M., and Humphreys W.G. (Eds). Drug Metabolism in Drug Design and Development: Basic Concepts and Practice (2007), John Wiley & Sons, Hoboken, NJ 447-476
22. Baillie T.A., and Davis M.R. Mass spectrometry in the analysis of glutathione conjugates. Biol. Mass Spectrom. 22 (1993) 319-325
23. Chen W.G., Zhang C., Avery M.J., and Fouda H. Reactive metabolite screen for reducing candidate attrition in drug discovery. In: Dansette P.M., Snyder R., Delaforge M., Goibson G.G., Greom H., Jollow D.J., Monks T.J., and Sipes I.G. (Eds). Biological Reactive Intermediates VI: Chemical and Biological Mechanisms in Susceptibility to and Prevention of Environmental Diseases (2001), Kluwer Academic/Plenum Publishers, New York 521-524
24. Yan Z., and Caldwell G.W. Stable-isotope trapping and high-throughput screenings of reactive metabolites using the isotope MS signature. Anal. Chem. 76 (2004) 6835-6847
25. Wen B., Ma L., Nelson S.D., and Zhu M. High-throughput screening and characterization of reactive metabolites using polarity switching of hybrid triple quadrupole linear ion trap mass spectrometry. Anal. Chem. 80 (2008) 1788-1799
26. Zhang H., and Yang Y. An algorithm for thorough background subtraction from high-resolution LC/MS data: application for detection of glutathione-trapped reactive metabolites. J. Mass Spectrom. (2008) 1181-1190
27. Zheng J., Ma L., Xin B., Olah T., Humphreys W.G., and Zhu M. Screening and identification of GSH-trapped reactive metabolites using hybrid triple quadruple linear ion trap mass spectrometry. Chem. Res. Toxicol. 20 (2007) 757-766
28. Zhu M., Ma L., Zhang H., and Humphreys W.G. Detection and structural characterization of glutathione-trapped reactive metabolites using liquid chromatography-high-resolution mass spectrometry and mass defect filtering. Anal. Chem. 79 (2007) 8333-8341
29. Castro-Perez J., Plumb R., Liang L., and Yang E. A high-throughput liquid chromatography/tandem mass spectrometry method for screening glutathione conjugates using exact mass neutral loss acquisition. Rapid Commun. Mass Spectrom. 19 (2005) 798-804
30. Caldwell G.W., and Yan Z. Screening for reactive intermediates and toxicity assessment in drug discovery. Curr. Opin. Drug Discov. Devel. 9 (2006) 47-60
31. Doss G.A., and Baillie T.A. Addressing metabolic activation as an integral component of drug design. Drug Metab. Rev. 38 (2006) 641-649
32. Shu Y.Z., Johnson B.M., and Yang T.J. Role of biotransformation studies in minimizing metabolism-related liabilities in drug discovery. AAPS J. 10 (2008) 178-192
33. Zhang D., and Comezoglu S.N. ADME studies in animals and humans: experimental design, metabolite profiling and identification, and data presentation. In: Zhang D., Zhu M., and Humphreys W.G. (Eds). Drug Metabolism in Drug Design and Development: Basic Concepts and Practice (2007), John Wiley & Sons, Hoboken, NJ 573-604
34. Zhang D., Ogan M., Gedamke R., Roongta V., Dai R., Zhu M., Rinehart J.K., Klunk L., and Mitroka J. Protein covalent binding of maxipost through a cytochrome P450-mediated ortho-quinone methide intermediate in rats. Drug Metab. Dispos. 31 (2003) 837-845
35. Gan J., Harper T.W., Hsueh M.M., Qu Q., and Humphreys W.G. Dansyl glutathione as a trapping agent for the quantitative estimation and identification of reactive metabolites. Chem. Res. Toxicol. 18 (2005) 896-903
36. Gorrod J.W., Whittlesea C.M., and Lam S.P. Trapping of reactive intermediates by incorporation of 14C-sodium cyanide during microsomal oxidation. Adv. Exp. Med. Biol. 283 (1991) 657-664
37. Masubuchi N., Makino C., and Murayama N. Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans. Chem. Res. Toxicol. 20 (2007) 455-464
38. Zhu M., Zhang D., and Skiles G. Quantification and structural elucidation of low quantities of radiolabeled metabolites using microplate scintillation counting (MSC) techniques in conjunction with LC-MS. In: Chowdhury S. (Ed). Identification and Quantification of Drugs, Metabolites and Metabolizing Enzymes by LC-MS (2005), Elsevier Science, Oxford, UK 195-225
39. Zhu M., Zhao W., and Humphreys W.G. Applications of liquid radiochromatography techniques in drug metabolism studies. In: Zhang D., Zhu M., and Humphreys W.G. (Eds). Drug Metabolism in Drug Design and Development: Basic Concepts and Practice (2007), John Wiley & Sons, Hoboken, NJ 289-318
40. Ma S., and Chowdhury S. Application of liquid chromatography/mass spectrometry for metabolite identification. In: Zhang D., Zhu M., and Humphreys W.G. (Eds). Drug Metabolism in Drug Design and Development: Basic Concepts and Practice (2007), John Wiley & Sons, Hoboken, NJ 319-367
41. Yan Z., Maher N., Torres R., Caldwell G.W., and Huebert N. Rapid detection and characterization of minor reactive metabolites using stable-isotope trapping in combination with tandem mass spectrometry. Rapid Commun. Mass Spectrom. 19 (2005) 3322-3330
42. Mutlib A., Lam W., Atherton J., Chen H., Galatsis P., and Stolle W. Application of stable isotope labeled glutathione and rapid scanning mass spectrometers in detecting and characterizing reactive metabolites. Rapid Commun. Mass Spectrom. 19 (2005) 3482-3492
43. Argoti D., Liang L., Conteh A., Chen L., Bershas D., Yu C.P., Vouros P., and Yang E. Cyanide trapping of iminium ion reactive intermediates followed by detection and structure identification using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Chem. Res. Toxicol. 18 (2005) 1537-1544
44. Yan Z., Maher N., Torres R., and Huebert N. Use of a trapping agent for simultaneous capturing and high-throughput screening of both "soft" and "hard" reactive metabolites. Anal. Chem. 79 (2007) 4206-4214
45. Alvarez-Sanchez R., Montavon F., Hartung T., and Pahler A. Thiazolidinedione bioactivation: a comparison of the bioactivation potentials of troglitazone, rosiglitazone, and pioglitazone using stable isotope-labeled analogues and liquid chromatography tandem mass spectrometry. Chem. Res. Toxicol. 19 (2006) 1106-1116
46. Dieckhaus C.M., Fernandez-Metzler C.L., King R., Krolikowski P.H., and Baillie T.A. Negative ion tandem mass spectrometry for the detection of glutathione conjugates. Chem. Res. Toxicol. 18 (2005) 630-638
47. Mahajan M.K., and Evans C.A. Dual negative precursor ion scan approach for rapid detection of glutathione conjugates using liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 22 (2008) 1032-1040
48. Clarke N.J., Rindgen D., Korfmacher W.A., and Cox K.A. Systematic LC/MS metabolite identification in drug discovery. Anal. Chem. 73 (2001) 430A-439A
49. Prakash C., Shaffer C.L., and Nedderman A. Analytical strategies for identifying drug metabolites. Mass Spectrom. Rev. 26 (2007) 340-369
50. Ma L., Wen B., Ruan Q., and Zhu M. Rapid screening of GSH-trapped reactive metabolites by linear ion trap mass spectrometry with isotope pattern-dependent scanning and post-acquisition data mining. Chem. Res. Toxicol. 21 (2008) 1477-1483
51. Wen B., Ma L., Rodrigues D., and Zhu M. Detection of novel reactive metabolites of trazodone: evidence for CYP2D6-mediated bioactivation of m-chlorophenylpiperazine. Drug Metab. Dispos. 36 (2008) 841-850
52. Wen B., Ma L., and Zhu M. Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem. Biol. Interact. 173 (2008) 59-67
53. B. Wen, W.L. Fitch, Screening and characterization of reactive metabolites using glutathione ethyl ester in combination with Q-trap mass spectrometry, J. Mass Spectrom., in press.
54. Soglia J.R., Harriman S.P., Zhao S., Barberia J., Cole M.J., Boyd J.G., and Contillo L.G. The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography-micro-electrospray ionization-tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent. J. Pharm. Biomed. Anal. 36 (2004) 105-116
55. Bauman J.N., Frederick K.S., Sawant A., Walsky R.L., Cox L.M., Obach R.S., and Kalgutkar A.S. Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug. Drug Metab. Dispos. 36 (2008) 1016-1029
56. Peterman S.M., Duczak Jr. N., Kalgutkar A.S., Lame M.E., and Soglia J.R. Application of a linear ion trap/orbitrap mass spectrometer in metabolite characterization studies: examination of the human liver microsomal metabolism of the non-tricyclic anti-depressant nefazodone using data-dependent accurate mass measurements. J. Am. Soc. Mass Spectrom. 17 (2006) 363-375
57. Sanders M., Shipkova P.A., Zhang H., and Warrack B.M. Utility of the hybrid LTQ-FTMS for drug metabolism applications. Curr. Drug Metab. 7 (2006) 547-555
58. Zhang H., Zhang D., and Ray K. A software filter to remove interference ions from drug metabolites in accurate mass liquid chromatography/mass spectrometric analyses. J. Mass Spectrom. 38 (2003) 1110-1112
59. Zhu M., Ma L., Zhang D., Ray K., Zhao W., Humphreys W.G., Skiles G., Sanders M., and Zhang H. Detection and characterization of metabolites in biological matrices using mass defect filtering of liquid chromatography/high resolution mass spectrometry data. Drug Metab. Dispos. 34 (2006) 1722-1733
60. Ruan Q., Peterman S., Szewc M.A., Ma L., Cui D., Humphreys W.G., and Zhu M. An integrated method for metabolite detection and identification using a linear ion trap/Orbitrap mass spectrometer and multiple data processing techniques: application to indinavir metabolite detection. J. Mass Spectrom. 43 (2008) 251-261
61. Bateman K.P., Castro-Perez J., Wrona M., Shockcor J.P., Yu K., Oballa R., and Nicoll-Griffith D.A. MSE with mass defect filtering for in vitro and in vivo metabolite identification. Rapid Commun. Mass Spectrom. 21 (2007) 1485-1496
62. Castro-Perez J.M. Current and future trends in the application of HPLC-MS to metabolite-identification studies. Drug Discov. Today 12 (2007) 249-256
63. Zhang H., Zhu M., Ray K.L., Ma L., and Zhang D. Mass defect profiles of biological matrices and the general applicability of mass defect filtering for metabolite detection. Rapid Commun. Mass Spectrom. 22 (2008) 2082-2088
64. Lim H.K., Chen J., Cook K., Sensenhauser C., Silva J., and Evans D.C. A generic method to detect electrophilic intermediates using isotopic pattern triggered data-dependent high-resolution accurate mass spectrometry. Rapid Commun. Mass Spectrom. 22 (2008) 1295-1311
65. Zhang H., Ma L., He K., and Zhu M. An algorithm for thorough background subtraction from high-resolution LC/MS data: application to the detection of troglitazone metabolites in rat plasma, bile, and urine. J. Mass Spectrom. 43 (2008) 1191-1200
66. Day S.H., Mao A., White R., Schulz-Utermoehl T., Miller R., and Beconi M.G. A semi-automated method for measuring the potential for protein covalent binding in drug discovery. J. Pharmacol. Toxicol. Methods 52 (2005) 278-285
67. Zhu M., Zhao W., Vazquez N., and Mitroka J.G. Analysis of low level radioactive metabolites in biological fluids using high-performance liquid chromatography with microplate scintillation counting: method validation and application. J. Pharm. Biomed. Anal. 39 (2005) 233-245
68. Soglia J.R., Contillo L.G., Kalgutkar A.S., Zhao S., Hop C.E., Boyd J.G., and Cole M.J. A semiquantitative method for the determination of reactive metabolite conjugate levels in vitro utilizing liquid chromatography-tandem mass spectrometry and novel quaternary ammonium glutathione analogues. Chem. Res. Toxicol. 19 (2006) 480-490
69. Al Janobi A.A., Mithen R.F., Gasper A.V., Shaw P.N., Middleton R.J., Ortori C.A., and Barrett D.A. Quantitative measurement of sulforaphane, iberin and their mercapturic acid pathway metabolites in human plasma and urine using liquid chromatography-tandem electrospray ionisation mass spectrometry. J. Chromatogr. B 844 (2006) 223-234
70. Li C.M., Hu C.W., and Wu K.Y. Quantification of urinary N-acetyl-S-(propionamide)cysteine using an on-line clean-up system coupled with liquid chromatography/tandem mass spectrometry. J. Mass Spectrom. 40 (2005) 511-515
71. Upadhyaya P., Rao P., Hochalter J.B., Li Z.Z., Villalta P.W., and Hecht S.S. Quantitation of N-acetyl-S-(9,10-dihydro-9-hydroxy-10-phenanthryl)-l-cysteine in human urine: comparison with glutathione-S-transferase genotypes in smokers. Chem. Res. Toxicol. 19 (2006) 1234-1240
72. Carmella S.G., Chen M., Zhang Y., Zhang S., Hatsukami D.K., and Hecht S.S. Quantitation of acrolein-derived (3-hydroxypropyl)mercapturic acid in human urine by liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry: effects of cigarette smoking. Chem. Res. Toxicol. 20 (2007) 986-990
73. Blair I.A. Endogenous glutathione adducts. Curr. Drug Metab. 7 (2006) 853-872
74. Baillie T.A., Cayen M.N., Fouda H., Gerson R.J., Green J.D., Grossman S.J., Klunk L.J., LeBlanc B., Perkins D.G., and Shipley L.A. Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 182 (2002) 188-196
75. USFDA, Guidance for Industry: Safety Testing of Drug Metabolites. www.fda.gov/CDER/GUIDANCE/6897fnl.pdf, 2008.
76. Humphreys W.G., and Unger S.E. Safety assessment of drug metabolites: characterization of chemically stable metabolites. Chem. Res. Toxicol. 19 (2006) 1564-1569
77. Smith D.A., and Obach R.S. Metabolites and safety: What are the concerns, and how should we address them?. Chem. Res. Toxicol. 19 (2006) 1570-1579
78. Kellert M., Scholz K., Wagner S., Dekant W., and Volkel W. Quantitation of mercapturic acids from acrylamide and glycidamide in human urine using a column switching tool with two trap columns and electrospray tandem mass spectrometry. J. Chromatogr. A 1131 (2006) 58-66
79. Scholz K., Dekant W., Volkel W., and Pahler A. Rapid detection and identification of N-acetyl-l-cysteine thioethers using constant neutral loss and theoretical multiple reaction monitoring combined with enhanced product-ion scans on a linear ion trap mass spectrometer. J. Am. Soc. Mass Spectrom. 16 (2005) 1976-1984
80. Wagner S., Scholz K., Donegan M., Burton L., Wingate J., and Volkel W. Metabonomics and biomarker discovery: LC-MS metabolic profiling and constant neutral loss scanning combined with multivariate data analysis for mercapturic acid analysis. Anal. Chem. 78 (2006) 1296-1305
81. Wagner S., Scholz K., Sieber M., Kellert M., and Voelkel W. Tools in metabonomics: an integrated validation approach for LC-MS metabolic profiling of mercapturic acids in human urine. Anal. Chem. 79 (2007) 2918-2926
82. Kellert M., Wagner S., Lutz U., and Lutz W.K. Biomarkers of furan exposure by metabolic profiling of rat urine with liquid chromatography-tandem mass spectrometry and principal component analysis. Chem. Res. Toxicol. 21 (2008) 761-768
83. Hollenberg P.F., Kent U.M., and Bumpus N.N. Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications. Chem. Res. Toxicol. 21 (2008) 189-205
84. Mitchell M.D., Elrick M.M., Walgren J.L., Mueller R.A., Morris D.L., and Thompson D.C. Peptide-based in vitro assay for the detection of reactive metabolites. Chem. Res. Toxicol. 21 (2008) 859-868
85. Kawai M., Sakurada I., Morita A., Iwamuro Y., Ando K., Omura H., Sakakibara S., Masuda T., Koike H., Honma T., Hattori K., Takashima T., Mizuno K., Mizutani M., and Kawamura M. Structure-activity relationship study of novel NR2B-selective antagonists with arylamides to avoid reactive metabolites formation. Bioorg. Med. Chem. Lett. 17 (2007) 5537-5542
86. Rietjens I.M., Cnubben N.H., van Haandel M., Tyrakowska B., Soffers A.E., and Vervoort J. Different metabolic pathways of 2,5-difluoronitrobenzene and 2,5-difluoroaminobenzene compared to molecular orbital substrate characteristics. Chem. Biol. Interact. 94 (1995) 49-72
87. Hop C.E., Chen Y., and Yu L.J. Uniformity of ionization response of structurally diverse analytes using a chip-based nanoelectrospray ionization source. Rapid Commun. Mass Spectrom. 19 (2005) 3139-3142
88. Ramanathan R., Zhong R., Blumenkrantz N., Chowdhury S.K., and Alton K.B. Response normalized liquid chromatography nanospray ionization mass spectrometry. J. Am. Soc. Mass Spectrom. 18 (2007) 1891-1899
89. Valaskovic G.A., Utley L., Lee M.S., and Wu J.T. Ultra-low flow nanospray for the normalization of conventional liquid chromatography/mass spectrometry through equimolar response: standard-free quantitative estimation of metabolite levels in drug discovery. Rapid Commun. Mass Spectrom. 20 (2006) 1087-1096
90. Kumar S., Kassahun K., Tschirret-Guth R.A., Mitra K., and Baillie T.A. Minimizing metabolic activation during pharmaceutical lead optimization: progress, knowledge gaps and future directions. Curr. Opin. Drug Discov. Devel. 11 (2008) 43-52
91. Dennehy M.K., Richards K.A., Wernke G.R., Shyr Y., and Liebler D.C. Cytosolic and nuclear protein targets of thiol-reactive electrophiles. Chem. Res. Toxicol. 19 (2006) 20-29
92. Liebler D.C. Protein damage by reactive electrophiles: targets and consequences. Chem. Res. Toxicol. 21 (2008) 117-128
93. Shin N.Y., Liu Q., Stamer S.L., and Liebler D.C. Protein targets of reactive electrophiles in human liver microsomes. Chem. Res. Toxicol. 20 (2007) 859-867
94. Wong H.L., and Liebler D.C. Mitochondrial protein targets of thiol-reactive electrophiles. Chem. Res. Toxicol. 21 (2008) 796-804
95. Liebler D.C., and Guengerich F.P. Elucidating mechanisms of drug-induced toxicity. Nat. Rev. Drug Discov. 4 (2005) 410-420